

Special Issue

Anticancer Drugs: Recent Advances and Challenges

Message from the Guest Editors

Technical advances in cell culture, robotics, computational biology, and development of reporter systems have transformed the field of drug discovery, enabling improved screening approaches for novel anticancer treatments. However, the translation of anticancer compounds identified in vitro into clinically active drugs has a limited success rate. The objective of the current Special Issue is to highlight success stories and/or novel processes of phenotype-based high-throughput drug screening in targeting malignant cells. Submission of studies describing computational approaches linking transcriptomic profiling of cancers with existing pharmaceutical compounds to accelerate drug repurposing or the use of CRISPR-based screening for the discovery of mechanisms of drug resistance and sensitization are strongly encouraged.

Guest Editors

Dr. Mouth Rafei

Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC H3T 1J4, Canada

Dr. Sebastien Talbot

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada

Deadline for manuscript submissions

closed (31 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/134070

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)